13
Biosimilars and Follow-On Biologics Global Market Outlook 2010-2025 - opportunities and challenges in this emerging market with high potential.pdf
In 2009, the biological (biologic) drug market generated over $125bn in revenues worldwide. There is great
demand for lower‐cost biological drugs. Commercial and regulatory developments will make biosimilars and
follow‐on biologics seize market share ‐ our new report explains how. Many biologic patents will expire during
our forecast period. There is mounting pressure from governments, insurers and patients´ groups to reduce
drug costs. Biologic drugs ‐ noted as some of the most‐expensive medicines ‐ are prime targets. Developments
facilitating biosimilars/follow‐on biologics are gaining momentum, with commercial opportunities for the
taking. The potential revenues are significant.
20
Amgen Inc. (AMGN)_ Biosimilars portfolio is well-positioned(1).pdf
Amgen Inc. (AMGN)_ Biosimilars portfolio is well-positioned(1)Amgen Inc. (AMGN)_ Biosimilars portfolio is well-positioned(1)Amgen Inc. (AMGN)_ Biosimilars portfolio is well-positioned(1)
20
a biodesign approach to obtain high yields of biosimilars by anti-apoptotic cell engineering a case study to increase the production yield of anti-.pdf
BioDesignApproach ObtainHigh Yieldsof Biosimilars Anti-apoptoticCell Engineering:a Case Study Produc
27
Biosimilars Are Here to Stay - aipla.org.pptx
PatentQuality ChemBIOTECHCHEM PARTNERSHIPBob StollDBRApril 201535 USC 112 Obviousness DraftingFocus2
21
2013-04-06 - ISHP - Biosimilars Handout-Rev 2013-03 ....pdf
2013-04-06 - ISHP - Biosimilars Handout-Rev 2013-03 …
7
Proceedings of the biosimilars workshop at the International Symposium on Oncology Pharmacy.pdf
Proceedings of the biosimilars workshop at the International Symposium on Oncology Pharmacy
9
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars.[2020][BioDrugs].pdf
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars.[2020][BioDrugs]
6
the danish model for the quick and safe implementation of infliximab and etanercept biosimilars.[2020][eur j clin pharmacol].pdf
the danish model for the quick and safe implementation of infliximab and etanercept biosimilars.[2020][eur j clin pharmacol]

向豆丁求助:有没有Biosimilars?

如要投诉违规内容,请联系我们按需举报;如要提出意见建议,请到社区论坛发帖反馈。